Pfizer (PFIZER.NS) Stock Price
Pfizer Price
Revenue has compounded at 6.7% per year over the past 20 years to 22.81 B INR. Earnings per share have grown at 10.5% per year over the last 20 years. Pfizer's net margin stands at 33.6%, up from 22.2% several years earlier. Pfizer currently offers a dividend yield of about 3.41%. The payout ratio is around 77% of earnings. The dividend has grown at 13.7% per year over the past 20 years. Analysts set a median price target of 6,222.00 INR, implying 63.4% above the current price. Of 8 analysts, 5 rate the stock a buy — an overall Buy consensus.
Pfizer stock price
Pfizer business model & stock analysis
Frequently asked questions about Pfizer
The business model of Pfizer Ltd revolves around pharmaceutical research, development, manufacturing, and sales. As a leading global biopharmaceutical company, Pfizer focuses on discovering breakthrough medicines and vaccines for various health conditions. With a diverse portfolio, Pfizer aims to improve patient lives and promote better health outcomes by investing in innovative research and development. Through strategic partnerships and collaborations, Pfizer strives to advance healthcare solutions while maintaining a strong commitment to delivering quality products. By upholding high standards of scientific integrity and ethical business practices, Pfizer continues to contribute to the well-being of individuals worldwide.
Pfizer Ltd is primarily active in the pharmaceutical industry. Its core business focuses on the research, development, manufacture, and sale of a wide range of pharmaceutical products. Pfizer Ltd is a renowned global pharmaceutical company, known for its breakthrough medicines and innovative therapies across various therapeutic areas. With a strong presence in the healthcare sector, Pfizer Ltd strives to enhance and improve the well-being of individuals worldwide.
The main competitors of Pfizer Ltd in the market include pharmaceutical companies such as Johnson & Johnson, Merck & Co., GlaxoSmithKline, and Novartis.
Pfizer Ltd. is a renowned pharmaceutical company with a rich history and background. Founded in 1849, Pfizer has evolved into a leading global player in the healthcare industry. With headquarters in the United States, the company has expanded its reach worldwide, including operations in India through Pfizer Ltd. Pfizer Ltd. is committed to discovering, developing, and manufacturing innovative medicines, vaccines, and consumer healthcare products. The company's relentless pursuit of medical advancements and dedication to improving people's lives has earned Pfizer Ltd. a strong reputation and recognition as a trusted name in the pharmaceutical sector.
Pfizer Ltd, a renowned pharmaceutical company, has achieved several significant milestones over the years. Notably, Pfizer is credited with the development of life-saving drugs like Viagra, Lipitor, and Zoloft, which have had a tremendous impact on global healthcare. Pfizer's contributions in the fields of immunology, oncology, and cardiology have not gone unnoticed, establishing the company as a leader in medical advancements. Pfizer's commitment to research and innovation has resulted in groundbreaking treatments, ensuring better clinical outcomes for patients worldwide. This dedication to excellence and their bold pursuit of scientific breakthroughs have made Pfizer Ltd a trusted and influential player in the pharmaceutical industry.
Pfizer Ltd, a leading pharmaceutical company, has a prominent presence in various countries and regions globally. The company operates in several key markets, including the United States, Europe, Asia-Pacific, Latin America, and Africa. With its headquarters in New York, Pfizer Ltd has established a strong foothold in the United States, utilizing its extensive network for research, development, and distribution of innovative healthcare solutions. Additionally, Pfizer Ltd's operations span across Europe, where it operates in numerous countries, catering to diverse healthcare needs. Further, the company's presence extends to the Asia-Pacific region, Latin America, and Africa, emphasizing its commitment to addressing global health challenges effectively.
Pfizer Ltd represents a set of core values and a strong corporate philosophy. As a renowned pharmaceutical company, Pfizer Ltd is committed to innovation and scientific advancement in the healthcare industry. The company believes in providing high-quality and safe medications to improve patient outcomes. Pfizer Ltd also emphasizes integrity, ethical practices, and transparency in all aspects of its operations. With a dedication to research and development, Pfizer Ltd aims to discover and deliver life-saving and life-enhancing therapies for people worldwide. This commitment, along with a customer-centric approach, makes Pfizer Ltd a trusted name in the pharmaceutical sector.
Analysts currently set an average price target of 6,389.08 INR for the Pfizer stock (median: 6,222.00 INR), implying +67.8 % versus the latest price. The consensus is based on 8 analyst ratings.
9 analysts currently rate the Pfizer stock: 6 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Pfizer to generate revenue of 25.29 B INR and earnings per share of 163.25 INR.
Converted at the current exchange rate, the Pfizer share trades at 35.15 EUR (3,808.20 INR).
The Pfizer share (PFIZER.NS) is listed on 2 stock exchanges, including: NSE (Indien) (PFIZER.NS).
Pfizer Ltd is a pharmaceutical company that focuses on the research, development, and marketing of products for the prevention and treatment of diseases. It has a global customer base and operates in various medical fields such as oncology, immunology, neurology, and infectious diseases. The company offers a wide range of medications, from well-established drugs to new therapies and biotechnological products. Its business model is centered on growth and profitability, with investments in research and development to remain competitive. Pfizer Ltd is organized into different divisions, including oncology, infectious diseases, immunology, and neurology, and also engages in the development of biotechnology products. Its products are marketed globally through pharmaceutical distribution channels. Overall, Pfizer Ltd strives to improve the health of patients worldwide through the development and marketing of innovative therapies.
The expected revenue of Pfizer is 25.29 B INR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pfizer is 7.47 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pfizer is currently 23.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pfizer stock.
The price-to-sales ratio (P/S) of Pfizer is currently 6.89. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pfizer stock.
The Eulerpool Quality Score for Pfizer is 5/10.
The ISIN of Pfizer is INE182A01018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Pfizer is PFIZER.NS. The ticker symbol is used to trade Pfizer shares on the stock exchange.
Pfizer stock
Pfizer Peer Group
Pfizer Ticker
Pfizer FIGI
All fundamentals and in-depth analysis of Pfizer
Our stock analysis for Pfizer stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pfizer. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.